Erratum: Building a network of ADPKD reference centres across Europe: the EuroCYST initiative(Nephrology Dialysis Transplantation) (2014) 29 :suppl 4 (iv26-iv32) doi: 10.1093/ndt/gfu091);Building a network of ADPKD reference centres across Europe: The EuroCYST initiative

Nephrology Dialysis Transplantation

Volumn 29, Issue , 2014, Pages iv26-iv32

  Petzold, Katja ^a   Gansevoort, Ron T ^b   Ong, Albert C M ^c   Devuyst, Olivier ^a   Rotar, Laura ^a   Eckardt, Kai Uwe ^d   Köttgen, Anna ^e   Pirson, Yves ^f   Remuzzi, Giuseppe ^g,h   Sandford, Richard ⁱ   Tesar, Vladimir ^j   Ecder, Tevfik ^k   Chaveau, Dominique ^l   Torra, Roser ^m   Budde, Klemens ⁿ   Le Meur, Yannick ^o   Wüthrich, Rudolf P ^p   Serra, Andreas L ^a,p  

^a UNIVERSITY OF ZURICH   (Switzerland)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^c UNIVERSITY OF SHEFFIELD   (United Kingdom)

^d UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^e UNIVERSITY OF FREIBURG   (Germany)

^f CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^g MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^h PAPA GIOVANNI XXIII HOSPITAL   (Italy)

ⁱ UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^j CHARLES UNIVERSITY   (Czech Republic)

^k ISTANBUL UNIVERSITY   (Turkey)

^l UNIVERSITÉ PAUL SABATIER   (France)

^m UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

ⁿ CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^o BREST UNIVERSITY HOSPITAL   (France)

^p UNIVERSITY HOSPITAL ZURICH   (Switzerland)

more..

Author keywords

ADPKD; Biomarker; Cohort; EuroCYST; Risk factors

Indexed keywords

ARTICLE; COHORT ANALYSIS; DISEASE COURSE; DISEASE SEVERITY; EUROPE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HEALTH CARE UTILIZATION; HEALTH ECONOMICS; HEALTH STATUS; HUMAN; KIDNEY POLYCYSTIC DISEASE; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MORBIDITY; MORTALITY; NUCLEAR MAGNETIC RESONANCE IMAGING; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PATIENT SELECTION; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITATIVE ANALYSIS; QUALITY OF LIFE; SOCIAL STATUS; TRANSLATIONAL RESEARCH; ADPKD; COHORT; EUROCYST; HEALTH CARE QUALITY; HEALTH SERVICE; METHODOLOGY; ORGANIZATION AND MANAGEMENT; PATHOPHYSIOLOGY; PATIENT REFERRAL; PROGNOSIS; QUESTIONNAIRE; RISK FACTOR; YOUNG ADULT;

BIOLOGICAL MARKER;

ADPKD; BIOMARKER; COHORT; EUROCYST; RISK FACTORS;

BIOLOGICAL MARKERS; EUROPE; GLOMERULAR FILTRATION RATE; HEALTH SERVICES; HEALTH STATUS; HUMANS; LONGITUDINAL STUDIES; MAGNETIC RESONANCE IMAGING; POLYCYSTIC KIDNEY, AUTOSOMAL DOMINANT; PROGNOSIS; QUESTIONNAIRES; REFERRAL AND CONSULTATION; RESEARCH DESIGN; STANDARD OF CARE; YOUNG ADULT;

EID: 84910125718     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfu358     Document Type: Erratum

References (30)

1. Torres VE, Harris PC, Pirson Y. Autosomal dominant polycystic kidney disease. Lancet 2007; 369: 1287-1301
2. Liebau MC, Serra AL. Looking at the (w)hole: magnet resonance imaging in polycystic kidney disease. Pediatr Nephrol 2013; 28: 1771-1783
3. Grantham JJ, Mulamalla S, Swenson-Fields KI. Why kidneys fail in autosomal dominant polycystic kidney disease. Nat Rev Nephrol 2011; 7: 556-566
4. Lentine KL, Xiao H, Machnicki G et al. Renal function and healthcare costs in patients with polycystic kidney disease. Clin J Am Soc Nephrol 2010; 5: 1471-1479
5. Torres VE, Harris PC. Autosomal dominant polycystic kidney disease: the last 3 years. Kidney Int 2009; 76: 149-168
6. Chang MY, Ong AC. Autosomal dominant polycystic kidney disease: recent advances in pathogenesis and treatment. Nephron Physiol 2008; 108: p1-p7
7. Wu M, Wahl PR, Le Hir M et al. Everolimus retards cyst growth and preserves kidney function in a rodent model for polycystic kidney disease. Kidney Blood Press Res 2007; 30: 253-259
8. Masyuk TV, Radtke BN, Stroope AJ. Pasireotide is more effective than octreotide in reducing hepatorenal cystogenesis in rodents with polycystic kidney and liver diseases. Hepatology 2013; 58: 409-421
9. Gattone VH, II, Wang X, Harris PC et al. Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist. Nat Med 2003; 9: 1323-1326
10. Serra AL, Poster D, Kistler AD et al. Sirolimus and kidney growth in autosomal dominant polycystic kidney disease. N Engl JMed 2010; 363: 820-829
11. Walz G, Budde K, Mannaa M et al. Everolimus in patients with autosomal dominant polycystic kidney disease. N Engl J Med 2010; 363: 830-840
12. Perico N, Antiga L, Caroli A et al. Sirolimus therapy to halt the progression of ADPKD. J Am Soc Nephrol 2010; 21: 1031-1040
13. Torres VE, Gansevoort RT, Czerwiec FS et al. Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med 2012; 367: 2407-2418
14. Caroli A, Perico N, Perna A et al. Effect of longacting somatostatin analogue on kidney and cyst growth in autosomal dominant polycystic kidney disease (ALADIN): a randomised, placebo-controlled, multicentre trial. Lancet 2013; 382: 1485-1495
15. Grantham JJ, Chapman AB, Torres VE. Volume progression in autosomal dominant polycystic kidney disease: the major factor determining clinical outcomes. J Am Soc Nephrol 2006; 1: 148-157
16. Helal I, Reed B, Schrier RW. Emergent early markers of renal progression in autosomal-dominant polycystic kidney disease patients: implications for prevention and treatment. Am J Nephrol 2012; 36: 162-167
17. Cornec-Le Gall E, Audrézet MP, Chen JM et al. Type of PKD1 mutation influences renal outcome in ADPKD. J Am Soc Nephrol 2013; 24: 1006-1013
18. Chapman AB, Guay-Woodford LM, Grantham JJ et al. Consortium for radiologic imaging studies of polycystic kidney disease cohort: renal structure in early autosomal-dominant polycystic kidney disease (ADPKD): the consortium for radiologic imaging studies of polycystic kidney disease (CRISP) cohort. Kidney Int 2003; 64: 1035-1045
19. Kistler AD, Poster D, Krauer F et al. Increases in kidney volume in autosomal dominant polycystic kidney disease can be detected within 6 months. Kidney Int 2009; 75: 235-241
20. Pei Y, Obaji J, Dupuis A et al. Unified criteria for ultrasonographic diagnosis of ADPKD. J Am Soc Nephrol 2009; 20: 205-212
21. Levey AS, Stevens LA, Schmid CH et al. A new equation to estimate glomerular filtration rate. Ann Intern Med 2009; 150: 604-612
22. Hunt SA, Abraham WT, Chin MH. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (writing committee to update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation 2005; 112: e154-e235
23. Lash JP, Go AS, Appel LJ et al. Chronic Renal Insufficiency Cohort (CRIC) Study: baseline characteristics and associations with kidney function. Clin J Am Soc Nephrol 2009; 4: 1302-1311
24. Imai E, Matsuo S, Makino H et al. Chronic Kidney Disease Japan Cohort (CKD-JAC) study: design and methods. Hypertens Res 2008; 31: 1101-1107
25. Eckardt KU, Bärthlein B, Baid-Agrawal S et al. The German Chronic Kidney Disease (GCKD) study: design and methods. Nephrol Dial Transplant 2012; 27: 1454-1460
26. Peterson RA, Kimmel PL, Sacks CR et al. Depression, perception of illness and mortality in patients with end-stage renal disease. Int J Psychiatry Med 1991; 21: 343-354
27. Kimmel PL, Weihs K, Peterson RA. Survival in hemodialysis patients: the role of depression. J Am Soc Nephrol 1993; 4: 12-27
28. Devins GM. Psychosocial issues in end-stage renal disease: introduction. Adv Ren Replace Ther 1994; 1: 195-197
29. Miskulin DC, Abebe KZ, Chapman AB et al. Health-related quality of life in patients with autosomal dominant polycystic kidney disease and CKD stages 1-4: a cross-sectional study. Am J Kidney Dis 2014; 63: 214-226
30. Devuyst O, Antignac C, Bindels R et al. The ERA-EDTAWorking Group on inherited kidney disorders. Nephrol Dial Transplant 2012; 27: 67-69